


1/38

*FIG. 1*




FIG. 2




FIG. 3




FIG. 4




FIG. 5A




FIG. 5B




FIG. 6A




FIG. 6B




FIG. 6C




FIG. 6D





FIG. 7A



▼ Part D

- HBV02 dose level and number of doses (up to 6 monthly doses) will be determined based on data from Parts B/C
- PEG-IFN weekly sc injections for 24 or 12 weeks
- 25 subjects/cohort: CHB patients without cirrhosis on NRTIs
- Target of 20 HBsAg negative and 5 HBsAg-positive subjects per cohort

FIG. 7B




FIG. 8




FIG. 9A

▼ Conducted at Auckland Clinical Studies in New Zealand




FIG. 9B

▼ Conducted at 14 sites in 5 countries: New Zealand, Australia, Hong Kong, Thailand, South Korea




FIG. 9C

17/38




FIG. 10A

18/38





FIG. 10B

19/38




FIG. 11

20/38




FIG. 12A

21/38





FIG. 12B

22/38

*FIG. 12C*

23/38




FIG. 13A

24/38




FIG. 13B




FIG. 13C

25/38




FIG. 13D




FIG. 13E




FIG. 14

27/38






FIG. 15A


28/38

*FIG. 15B*

29/38

*FIG. 16*

30/38


*FIG. 17*

31/38


	50 mg n=6	100 mg n=5 ^a	200 mg n=6	400 mg n=7 ^b	600 mg n=6	900 mg n=6
HBV02						
AUC ₀₋₁₂ , h·ng/mL	1200 (24.6)	3230 (32.5)	5480 (28.2)	16800 (32.9)	17700 (30.9)	44300 (17.9)
AUC _{last} , h·ng/mL	1260 (21.2)	3700 (31.9)	6570 (17.6)	21400 (25.9)	28000 (27.0)	59000 (15.5)
C _{max} , ng/mL	155 (42.1)	355 (32.9)	711 (29.2)	1940 (41.2)	1830 (33.5)	5014 (12.6)
T _{max} , h	4.00 (1.00, 4.00)	4 (4.00, 6.00)	5.00 (4.00, 6.50)	8.00 (4.00, 8.00)	7.00 (5.50, 10.0)	4.00 (3.50, 8.50)
T _{last} , h	12.0 (12.0, 15.0)	12.0 (12.0, 24.0)	24.0 (21.0, 24.0)	24.0 (24.0, 24.0)	24.0 (24.0, 48.0)	24.0 (24.0, 48.0)
AS(N-1)3' HBV02						
AUC ₀₋₁₂ , h·ng/mL	BLQ	NC	233 (27.3)	871 (47.2)	726 (52.4)	2030 (23.3)
AUC _{last} , h·ng/mL	BLQ	205 (186) ^c	475 (31.2)	2253 (39.2)	2670 (54.7)	6380 (23.4)
C _{max} , ng/mL	BLQ	26.3 (168) ^c	62.4 (28.2)	234 (52.2)	177 (55.9)	515 (20.6)
T _{max} , h	NC	6.00 (5.00, 6.00) ^c	6.00 (4.00, 6.50)	8.00 (4.00, 10.0)	10.0 (8.00, 10.0)	8.00 (4.00, 10.0)
T _{last} , h	NC	8.00 (6.00, 9.00) ^c	12.0 (10.0, 10.0)	12.0 (12.0, 24.0)	24.0 (21.0, 24.0)	24.0 (24.0, 24.0)
MR _{Cmax}	NC	0.074 ^c	0.088	0.121	0.097	0.103
MR _{AUC0-12}	NC	NC	0.094	0.115	0.090	0.110

FIG. 18

32/38

*FIG. 19A*

33/38

*FIG. 19B*

	50 mg n=6	100 mg n=5 ^a	200 mg n=6	400 mg n=7 ^b	600 mg n=6	900 mg n=6
HBV02						
AUC ₀₋₂₄ , h·ng/mL	1360 (15.8) ^c	4080 (29.1) ^c	6920 (26.9)	21100 (26.8)	26700 (29.4)	57400 (15.9)
CL _{R/F} , L/h	6.21 (16.4)	5.32 (22.4)	6.71 (11.9)	5.24 (17.8)	7.28 (20.2)	7.22 (19.1)
Urine fe ₀₋₂₄ , %	17.0 (18.8)	18.3 (34.0)	23.2 (18.7)	27.6 (26.0)	32.3 (36.1)	46.1 (20.6)
AS(N-1)3' HBV02						
AUC ₀₋₂₄ , ng·h/mL	BLQ	NC	683 (28.3)	2629 (45.3)	3090 (36.8)	6380 (23.4)
CL _{R/F} , L/h	NC	NC	21.4 (17.2)	15.4 (31.3)	17.7 (22.3)	21.7 (8.94)
Urine fe ₀₋₂₄ , %	1.95 (24.8)	4.20 (54.8)	3.31 (20.1)	4.62 (26.5)	4.15 (55.6)	6.96 (21.1)

FIG. 20

35/38




FIG. 21A

36/38




FIG. 21B




FIG. 22

38/38




FIG. 23




FIG. 24